
Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
Keywords: متالوتیژیون; AKT; v-akt murine thymoma viral oncogene homolog; ANOVA; analysis of variance; ATCC; American Type Culture Collection; BRAF; v-raf murine sarcoma viral oncogene homolog B1; BRAFm; BRAF mutation; CKIT; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene